Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Notes Payables (2021 - 2022)

Verrica Pharmaceuticals has reported Notes Payables over the past 2 years, most recently at $42.3 million for Q2 2022.

  • Quarterly results put Notes Payables at $42.3 million for Q2 2022, up 3.14% from a year ago — trailing twelve months through Jun 2022 was $42.3 million (up 3.14% YoY), and the annual figure for FY2021 was $41.7 million, changed.
  • Notes Payables for Q2 2022 was $42.3 million at Verrica Pharmaceuticals, up from $42.0 million in the prior quarter.
  • Over the last five years, Notes Payables for VRCA hit a ceiling of $42.3 million in Q2 2022 and a floor of $40.0 million in Q1 2021.